Principal Financial Group Inc. Has $29.53 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Principal Financial Group Inc. boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 18.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 367,735 shares of the medical equipment provider's stock after acquiring an additional 56,432 shares during the period. Principal Financial Group Inc. owned about 0.53% of Lantheus worth $29,525,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. International Assets Investment Management LLC acquired a new position in Lantheus during the 4th quarter worth $407,000. Retirement Systems of Alabama grew its position in Lantheus by 0.4% in the 4th quarter. Retirement Systems of Alabama now owns 85,779 shares of the medical equipment provider's stock valued at $5,318,000 after buying an additional 336 shares in the last quarter. First Horizon Advisors Inc. grew its position in Lantheus by 103.9% in the 4th quarter. First Horizon Advisors Inc. now owns 932 shares of the medical equipment provider's stock valued at $58,000 after buying an additional 475 shares in the last quarter. M&T Bank Corp acquired a new position in Lantheus during the 4th quarter valued at about $320,000. Finally, MeadowBrook Investment Advisors LLC bought a new stake in shares of Lantheus during the 4th quarter worth about $189,000. Institutional investors own 99.06% of the company's stock.

Insider Activity

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total transaction of $27,201.57. Following the completion of the sale, the chief accounting officer now owns 62,557 shares of the company's stock, valued at $4,990,171.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total transaction of $27,201.57. Following the completion of the transaction, the chief accounting officer now owns 62,557 shares of the company's stock, valued at approximately $4,990,171.89. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now owns 21,221 shares of the company's stock, valued at $2,047,402.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,193 shares of company stock valued at $3,949,202. Insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. JMP Securities decreased their price objective on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Truist Financial lowered their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research report on Thursday, August 1st. Leerink Partners upped their price objective on Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Finally, B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $119.00.

Lantheus Stock Up 1.6 %

NASDAQ LNTH traded up $1.66 on Monday, reaching $106.47. The stock had a trading volume of 716,900 shares, compared to its average volume of 1,048,601. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The business has a 50 day moving average price of $100.67 and a 200 day moving average price of $80.26. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $7.38 billion, a price-to-earnings ratio of 16.25 and a beta of 0.51.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus's revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.40 EPS. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.03 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.